Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2)

about

Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2)

Item

http://www.wikidata.org/entity/Q36522939

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Low Dose Cytosine Arabinoside ...... with Excess Blasts (MDS-RAEB2)

@ast

Low Dose Cytosine Arabinoside ...... with Excess Blasts (MDS-RAEB2)

@en

type

Item

label

Low Dose Cytosine Arabinoside ...... with Excess Blasts (MDS-RAEB2)

@ast

Low Dose Cytosine Arabinoside ...... with Excess Blasts (MDS-RAEB2)

@en

prefLabel

Low Dose Cytosine Arabinoside ...... with Excess Blasts (MDS-RAEB2)

@ast

Low Dose Cytosine Arabinoside ...... with Excess Blasts (MDS-RAEB2)

@en

P1476

Low Dose Cytosine Arabinoside ...... with Excess Blasts (MDS-RAEB2)

@en

P2093

Elif Birtaş Ateşoğlu

http://www.w3.org/2001/XMLSchema#string

Figen Atalay

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia.

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.

P2888

s12288-015-0509-2

P304

46-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12288-015-0509-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276301049

http://www.w3.org/2001/XMLSchema#string

P698

26855506

http://www.w3.org/2001/XMLSchema#string

P932

4733667

http://www.w3.org/2001/XMLSchema#string